Thomas Cannell, Sesen Bio CEO

Sesen takes next step af­ter in­vestor at­tack, calls for share­hold­er vote to ap­prove merg­er

Two and a half weeks af­ter Sesen Bio pushed back against an in­vestor group op­pos­ing a merg­er with Caris­ma Ther­a­peu­tics, the biotech is mov­ing for­ward …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.